ArticlemSphere2020
Robustness of Serologic Investigations for Chikungunya and Mayaro Viruses following Coemergence.
Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- Review
- Identification of multiple arbovirus infections/exposure in Northeastern Brazil using a multiplex microsphere immunoassay.Journal of clinical microbiology · 2026Article
- Development and evaluation of a duplex RT-qPCR assay for the detection and identification of Mayaro and chikungunya viruses.Journal of clinical microbiology · 2025Article
- Effect of chikungunya, Mayaro and Una virus coinfection on vector competence ofOne health (Amsterdam, Netherlands) · 2025Article
- Pathogenesis and clinical management of arboviral diseases.World journal of virology · 2025Review
- Exposure to non-endemic arboviruses (alphaviruses) in Costa Rica assessed from human samples collected in areas with contrasting levels of dengue endemicity.Frontiers in public health · 2025Article
- Rio Mamore Hantavirus Endemicity, Peruvian Amazon, 2020.Emerging infectious diseases · 2024Article
- Chikungunya Outbreak Risks after the 2014 Outbreak, Dominican Republic.Emerging infectious diseases · 2024Article
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- A cluster of Mayaro virus infections in a film team returning from Suriname, February 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Mayaro Virus: An Emerging Alphavirus in the Americas.Viruses · 2024Review
- Article
- A geopositioned and evidence-graded pan-species compendium of Mayaro virus occurrence.Scientific data · 2023Article
- Chikungunya fever.Nature reviews. Disease primers · 2023Review
- Serological and molecular evidence of chikungunya virus infection among febrile outpatients seeking healthcare in Northern Malawi.Infection ecology & epidemiology · 2023Article
- Understanding the Biology and Immune Pathogenesis of Chikungunya Virus Infection for Diagnostic and Vaccine Development.Viruses · 2022Review
- Arbovirus Antibody Seroprevalence in the Human Population from Cauca, Colombia.The American journal of tropical medicine and hygiene · 2022Article
- Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus.International journal of molecular sciences · 2022Article
- Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 2013, the arthropod-borne Chikungunya virus (CHIKV) has cocirculated with the autochthonous Mayaro virus (MAYV) in Latin America. Both belong to the same alphavirus serocomplex, termed the Semliki Forest serocomplex. The extent of antibody cross-reactivity due to the antigenic relatedness of CHIKV and MAYV in commonly used serologic tests remains unclear. By testing 64 CHIKV- and 37 MAYV-specific sera from cohort studies conducted in Peru and Brazil, we demonstrate about 50% false-positive test results using commercially available enzyme-linked immunosorbent assays (ELISAs) based on structural antigens. In contrast, combining ELISAs for CHIKV and MAYV significantly increased positive predictive values (PPV) among all cohorts from 35.3% to 88.2% for IgM and from 61.3% to 96.8% for IgG (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.